Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2016

Open Access 01-12-2016 | Research

Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1

Authors: Rashi Arora, Sharad Sawney, Vikas Saini, Chris Steffi, Manisha Tiwari, Daman Saluja

Published in: Molecular Cancer | Issue 1/2016

Login to get access

Abstract

Background

A handful of studies have exploited antitumor potential of esculetin, a dihydroxy coumarine derivative; the targets to which it binds and the possible downstream mechanism for its cytotoxicity in cancer cells remain to be elucidated. Using pancreatic cancer cell lines as a model system, herein the study was initiated to check the efficacy of esculetin in inhibiting growth of these cancer cells, to decipher mechanism of its action and to predict its direct binding target protein.

Methods

The cytotoxicity of esculetin was determined in PANC-1, MIA PaCa-2 and AsPC-1 cell lines; followed by an inspection of intracellular levels of ROS and its associated transcription factor, p65-NF-κB. The interaction between transcription factor, Nrf2 and its regulator KEAP1 was studied in the presence and absence of esculetin. The effect of Nrf2 on gene expression of antioxidant response element pathway was monitored by real time PCR. Thereafter, potential binding target of esculetin was predicted through molecular docking and then confirmed in vitro.

Results

Esculetin treatment in all three pancreatic cancer cell lines resulted in significant growth inhibition with G1-phase cell cycle arrest and induction of mitochondrial dependent apoptosis through activation of caspases 3, 8 and 9. A notable decrease was observed in intracellular ROS and protein levels of p65-NF-κB in PANC-1 cells on esculetin treatment. Antioxidant response regulator Nrf2 has been reportedly involved in crosstalk with NF-κB. Interaction between Nrf2 and KEAP1 was found to be lost upon esculetin treatment in PANC-1 and MIA Paca-2 cells. Nuclear accumulation of Nrf2 and an upregulation of expression of Nrf2 regulated gene NQO1, observed on esculetin treatment in PANC-1 further supported the activation of Nrf2. To account for the loss of Nrf2-KEAP1 interaction on esculetin treatment, direct binding potential between esculetin and KEAP1 was depicted in silico using molecular docking studies. Pull down assay using esculetin conjugated sepharose beads confirmed the binding between esculetin and KEAP1.

Conclusions

We propose that esculetin binds to KEAP1 and inhibits its interaction with Nrf2 in pancreatic cancer cells. This thereby promotes nuclear accumulation of Nrf2 in PANC-1 cells that induces antiproliferative and apoptotic response possibly by attenuating NF-κB.
Appendix
Available only for authorised users
Literature
1.
Bhanot A, Sharma R, Noolvi MN. Natural sources as potential anti-cancer agents: a review. Int J Phytomedicine. 2011;3:09–26.
2.
Kinghorn AD, Chin Y-W, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Discov Devel. 2009;12:189–96.PubMedPubMedCentral
3.
Kawaii S, Tomono Y, Ogawa K, Sugiura M, Yano M, Yoshizawa Y. The antiproliferative effect of coumarins on several cancer cell lines. Anticancer Res. 2001;21:917–23.PubMed
4.
Chang WS, Lin CC, Chuang SC, Chiang HC. Superoxide anion scavenging effect of coumarins. Am J Chin Med. 1996;24:11–7.CrossRefPubMed
5.
Yue J-M, Xu J, Zhao Y, Sun H-D, Lin Z-W. Chemical components from ceratostigma willmottianum. J Nat Prod. 1997;60:1031–3.CrossRef
6.
Chu CY, Tsai YY, Wang CJ, Lin WL, Tseng TH. Induction of apoptosis by esculetin in human leukemia cells. Eur J Pharmacol. 2001;416:25–32.CrossRefPubMed
7.
Park C, Jin C-Y, Kim G-Y, Choi I-W, Kwon TK, Choi BT, Lee SJ, Lee WH, Choi YH. Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK. Toxicol Appl Pharmacol. 2008;227:219–28.CrossRefPubMed
8.
Park C, Jin CY, Kwon HJ, Hwang HJ, Kim GY, Choi IW, Kwon TK, Kim BW, Kim WJ, Choi YH. Induction of apoptosis by esculetin in human leukemia U937 cells: Roles of Bcl-2 and extracellular-regulated kinase signaling. Toxicol in Vitro. 2010;24:486–94.CrossRefPubMed
9.
Yang J, Xiao Y-L, He X-R, Qiu G-F, Hu X-M. Aesculetin-induced apoptosis through a ROS-mediated mitochondrial dysfunction pathway in human cervical cancer cells. J Asian Nat Prod Res. 2010;12:185–93.CrossRefPubMed
10.
Rubio V, Calviño E, García-Pérez A, Herráez A, Diez JC. Human acute promyelocytic leukemia NB4 cells are sensitive to esculetin through induction of an apoptotic mechanism. Chem Biol Interact. 2014;220:129–39.CrossRefPubMed
11.
Kim AD, Han X, Piao MJ, Hewage SRKM, Hyun CL, Cho SJ, Hyun JW. Esculetin induces death of human colon cancer cells via the reactive oxygen species-mediated mitochondrial apoptosis pathway. Environ Toxicol Pharmacol. 2015;39:982–9.CrossRefPubMed
12.
Wang J, Lu ML, Dai HL, Zhang SP, Wang HX, Wei N. Esculetin, a coumarin derivative, exerts in vitro and in vivo antiproliferative activity against hepatocellular carcinoma by initiating a mitochondrial-dependent apoptosis pathway. Braz J Med Biol Res. 2015;48:245–53.CrossRefPubMed
13.
Sawney S, Arora R, Aggarwal KK, Saluja D. Esculetin downregulates the expression of AML1-ETO and C-Kit in Kasumi-1 cell line by decreasing half-life of mRNA. J Oncol. 2015;2015:781473.CrossRefPubMedPubMedCentral
14.
Sawney S, Arora P, Steffi C, Chandra V, Ali M, Kamal K. Esculetin induces apoptosis in human leukemia Kasumi-1 cells through Caspase 3 activation. J Innov Pharm Biol Sci. 2015;2:273–89.
15.
Payá M, Halliwell B, Hoult JRS. Interactions of a series of coumarins with reactive oxygen species. Biochem Pharmacol. 1992;44:205–14.CrossRefPubMed
16.
17.
Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 2012;32:687–726.CrossRefPubMedPubMedCentral
18.
Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76–86.CrossRefPubMedPubMedCentral
19.
McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem. 2003;278:21592–600.CrossRefPubMed
20.
Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003;23:8137–51.CrossRefPubMedPubMedCentral
21.
Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal. 2012;16:1295–322.CrossRefPubMedPubMedCentral
22.
Jiang Z-Y, Lu M-C, Xu LL, Yang T-T, Xi M-Y, Xu X-L, Guo X-K, Zhang X-J, You Q-D, Sun H-P. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis. J Med Chem. 2014;57:2736–45.CrossRefPubMed
23.
Probst BL, Trevino I, McCauley L, Bumeister R, Dulubova I, Wigley WC, Ferguson DA. RTA 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. PLoS One. 2015;10:e0122942.CrossRefPubMedPubMedCentral
24.
Lee S-Y, Lim T-G, Chen H, Jung SK, Lee H-J, Lee M-H, Kim DJ, Shin A, Lee KW, Bode AM, Surh Y-J, Dong Z. Esculetin suppresses proliferation of human colon cancer cells by directly targeting β-catenin. Cancer Prev Res (Phila). 2013;6:1356–64.CrossRef
25.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.CrossRefPubMed
26.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.CrossRefPubMed
27.
Cohen R, Neuzillet C, Tijeras-Raballand A, Faivre S, de Gramont A, Raymond E. Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget. 2015;19:16832–47.CrossRef
28.
Park S-S, Park S-K, Lim J-H, Choi YH, Kim W-J, Moon S-K. Esculetin inhibits cell proliferation through the Ras/ERK1/2 pathway in human colon cancer cells. Oncol Rep. 2011;25:223–30.PubMed
29.
Yun E-S, Park S-S, Shin H-C, Choi YH, Kim W-J, Moon S-K. p38 MAPK activation is required for esculetin-induced inhibition of vascular smooth muscle cells proliferation. Toxicol In Vitro. 2011;25:1335–42.CrossRefPubMed
30.
Lee JK, Edderkaoui M, Truong P, Ohno I, Jang K-T, Berti A, Pandol SJ, Gukovskaya AS. NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases. Gastroenterology. 2007;133:1637–48.CrossRefPubMed
31.
Ruiz-Ramos R, Lopez-Carrillo L, Rios-Perez AD, De Vizcaya-Ruíz A, Cebrian ME. Sodium arsenite induces ROS generation, DNA oxidative damage, HO-1 and c-Myc proteins, NF-kappaB activation and cell proliferation in human breast cancer MCF-7 cells. Mutat Res. 2009;674:109–15.CrossRefPubMed
32.
Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol. 2005;70:700–13.CrossRefPubMed
33.
Kaltschmidt B, Kaltschmidt C, Hehner SP, Dröge W, Schmitz ML. Repression of NF-kappaB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators. Oncogene. 1999;18:3213–25.CrossRefPubMed
34.
Das L, Vinayak M. Anti-carcinogenic action of curcumin by activation of antioxidant defence system and inhibition of NF-κB signalling in lymphoma-bearing mice. Biosci Rep. 2012;32:161–70.CrossRefPubMed
35.
Martín V, Herrera F, García-Santos G, Antolín I, Rodriguez-Blanco J, Rodriguez C. Signaling pathways involved in antioxidant control of glioma cell proliferation. Free Radic Biol Med. 2007;42:1715–22.CrossRefPubMed
36.
Ma Q, Kinneer K, Ye J, Chen BJ. Inhibition of nuclear factor kappaB by phenolic antioxidants: interplay between antioxidant signaling and inflammatory cytokine expression. Mol Pharmacol. 2003;64:211–9.CrossRefPubMed
37.
Cuadrado A, Martín-Moldes Z, Ye J, Lastres-Becker I. Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation. J Biol Chem. 2014;289:15244–58.CrossRefPubMedPubMedCentral
38.
Hu M-L. Dietary polyphenols as antioxidants and anticancer agents: more questions than answers. Chang Gung Med J. 2011;34:449–60.PubMed
39.
Nair S, Doh ST, Chan JY, Kong A-N, Cai L. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer. 2008;99:2070–82.CrossRefPubMedPubMedCentral
40.
Li W, Khor TO, Xu C, Shen G, Jeong W-S, Yu S, Kong A-N. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol. 2008;76:1485–9.CrossRefPubMedPubMedCentral
41.
Kwak MK, Kensler TW. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol. 2010;244:66–76.CrossRefPubMed
42.
Keum YS, Choi BY. Molecular and chemical regulation of the keap1-Nrf2 signaling pathway. Molecules. 2014;19:10074–89.CrossRefPubMed
43.
Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, Copple IM, Williams S, Owen A, Neoptolemos JP, Goldring CE, Park BK. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer. 2011;10:37.CrossRefPubMedPubMedCentral
44.
Kansanen E, Kuosmanen SM, Leinonen H, Levonenn AL. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013;1:45–9.CrossRefPubMedPubMedCentral
45.
Furfaro AL, Traverso N, Domenicotti C, Piras S, Moretta L, Marinari UM, Pronzato MA, Nitti M. The Nrf2 / HO-1 Axis in cancer cell growth and chemoresistance. Oxid Med Cell Longev. 2015;2016:1958174.PubMedPubMedCentral
46.
Hur W, Gray NS. Small molecule modulators of antioxidant response pathway. Curr Opin Chem Biol. 2011;15:162–73.CrossRefPubMed
47.
Marcotte D, Zeng W, Hus JC, McKenzie A, Hession C, Jin P, Bergeron C, Lugovskoy A, Enyedy I, Cuervo H, Wang D, Atmanene C, Roecklin D, Vecchi M, Vivat V, Kraemer J, Winkler D, Hong V, Chao J, Lukashev M, Silvian L. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. Bioorg Med Chem. 2013;21:4011–9.CrossRefPubMed
48.
Loboda A, Rojczyk-Golebiewska E, Bednarczyk-Cwynar B, Zaprutko L, Jozkowicz A, Dulak J. Targeting Nrf2-mediated gene transcription by triterpenoids and their derivatives. Biomol Ther. 2012;20:499–505.CrossRef
49.
Saw C, Wu Q, Kong A-NT, Gillis C, Yue P, Mak N, Cheng Y, Leung K, Ng T, Fan D, Yeung H, Wong R, Helms S, Saita T, Katano M, Matsunaga H, Kouno I, Fujito H, Mori M, Matsunaga H, Saita T, Nagumo F, Mori M, Katano M, Yun T, Li W, Kong A, Gum S, Jo S, Ahn S, et al. Anti-cancer and potential chemopreventive actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-inflammatory pathways. Chin Med. 2010;5:37.CrossRefPubMedPubMedCentral
50.
Wang Y-Y, Zhou G-B, Yin T, Chen B, Shi J-Y, Liang W-X, Jin X-L, You J-H, Yang G, Shen Z-X, Chen J, Xiong S-M, Chen G-Q, Xu F, Liu Y-W, Chen Z, Chen S-J. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A. 2005;102:1104–9.CrossRefPubMedPubMedCentral
51.
Tong Y-H, Zhang B, Fan Y, Lin N-M. Keap1–Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics. Chron Dis Transl Med. 2015;1:175–86.
52.
53.
NAIR S, LI W, KONG A-NT. Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells. Acta Pharmacol Sin. 2007;28:459–72.CrossRefPubMed
54.
Wang Y-Y, Zhe H, Zhao R, Hanahan D, Weinberg R, Hanahan D, Weinberg R, Patlolla J, Rao C, Petronelli A, Pannitteri G, Testa U, Liby K, Sporn M, Yadav V, Prasad S, Sung B, Kannappan R, Aggarwal B, Liby K, Yore M, Sporn M, Ovesná Z, Vachálková A, Horváthová K, Tóthová D, Bishayee A, Ahmed S, Brankov N, Perloff M, et al. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment. Mol Cancer. 2014;13:30.CrossRefPubMedPubMedCentral
55.
56.
Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol. 2006;26:2887–900.CrossRefPubMedPubMedCentral
57.
Lo S-C, Li X, Henzl MT, Beamer LJ, Hannink M. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J. 2006;25:3605–17.CrossRefPubMedPubMedCentral
Metadata
Title
Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1
Authors
Rashi Arora
Sharad Sawney
Vikas Saini
Chris Steffi
Manisha Tiwari
Daman Saluja
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2016
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-016-0550-2

Other articles of this Issue 1/2016

Molecular Cancer 1/2016 Go to the issue

Erratum

Erratum to: ‘Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells’

Review

Detection of cancer cells using SapC-DOPS nanovesicles

Research

Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells – evidence for a role in hepatocellular carcinoma growth in vivo

Research

MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression

Research

Aurora kinase targeting in lung cancer reduces KRAS-induced transformation

Research

HOXA7 plays a critical role in metastasis of liver cancer associated with activation of Snail
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits